Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Jian Jun Zou"'
Autor:
Song-Yang Wu, Ying Xu, Li Chen, Lei Fan, Xiao-Yan Ma, Shen Zhao, Xiao-Qing Song, Xin Hu, Wen-Tao Yang, Wen-Jun Chai, Xiao-Mao Guo, Xi-Zi Chen, Yan-Hui Xu, Xiao-Yu Zhu, Jian-Jun Zou, Zhong-Hua Wang, Yi-Zhou Jiang, Zhi-Ming Shao
Publikováno v:
Molecular Cancer, Vol 21, Iss 1, Pp 1-15 (2022)
Abstract Background Immune checkpoint inhibitors had a great effect in triple-negative breast cancer (TNBC); however, they benefited only a subset of patients, underscoring the need to co-target alternative pathways and select optimal patients. Herei
Externí odkaz:
https://doaj.org/article/e0dbceec56ca46efaf601443a7bfe647
Autor:
Shan Su, Mei-Feng Ye, Xiao-Ting Cai, Xue Bai, Zhi-Hao Huang, Si-Cong Ma, Jian-Jun Zou, Yu-Xiang Wen, Li-Juan Wu, Xue-Jun Guo, Xian-Lan Zhang, Wen-Chang Cen, Duo-Hua Su, Hui-Yi Huang, Zhong-Yi Dong
Publikováno v:
BMC Medicine, Vol 19, Iss 1, Pp 1-11 (2021)
Abstract Background It is not a rare clinical scenario to have patients presenting with coexisting malignant tumor and tuberculosis. Whether it is feasible to conduct programmed death-(ligand) 1 [PD-(L)1] inhibitors to these patients, especially thos
Externí odkaz:
https://doaj.org/article/895224225a4443428766e35a13dfa42b
Autor:
Pai-Sen Yu, Chia-Ju Liao, Min-Te Chen, Jian-Jun Zou, Xuefa Shi, A. A. Bosin, Sergey A. Gorbarenko, Yusuke Yokoyama
Publikováno v:
Progress in Earth and Planetary Science, Vol 7, Iss 1, Pp 1-13 (2020)
Abstract We investigated an alkenone-based sea surface temperature (SST) and the hydrographic change records of the subarctic Northwestern (NW) Pacific from the last glacial to interglacial. The core we investigated is a piston core (LV 63-41-2, 52.5
Externí odkaz:
https://doaj.org/article/e0469d1c2dda44daadccbcf87568eda4
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2020)
Background and Objective: Clopidogrel (CLOP) is commonly used in coronary artery disease (CAD) patients with or without diabetes (DM), but these patients often suffer CLOP resistance, especially those with diabetes. This study was aimed to develop a
Externí odkaz:
https://doaj.org/article/cc87285573c64798aeaf1a5118e45def
Autor:
Zhi-Ming Shao, Zhong-Hua Wang, Wen-Tao Yang, Jian-Jun Zou, Xiao-Yu Zhu, Yanhui Xu, Xizi Chen, Xiaomao Guo, Wen-Jun Chai, Xiang-Jie Sun, Ying Xu, Xiao-Yan Ma, Shen Zhao, Xin Hu, A-Yong Cao, Xiao-Yan Huang, Can-Ming Chen, Zhen Hu, Yi-Feng Hou, Jun-Jie Li, Lei Fan, Ke-Da Yu, Guang-Yu Liu, Gen-Hong Di, Jiong Wu, Song-Yang Wu, Yi-Zhou Jiang, Li Chen
Supplementary Data from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cf9dd20e1c2e70c6f874ea9cfec3cb9
https://doi.org/10.1158/1078-0432.22487412.v1
https://doi.org/10.1158/1078-0432.22487412.v1
Autor:
Zhi-Ming Shao, Zhong-Hua Wang, Wen-Tao Yang, Jian-Jun Zou, Xiao-Yu Zhu, Yanhui Xu, Xizi Chen, Xiaomao Guo, Wen-Jun Chai, Xiang-Jie Sun, Ying Xu, Xiao-Yan Ma, Shen Zhao, Xin Hu, A-Yong Cao, Xiao-Yan Huang, Can-Ming Chen, Zhen Hu, Yi-Feng Hou, Jun-Jie Li, Lei Fan, Ke-Da Yu, Guang-Yu Liu, Gen-Hong Di, Jiong Wu, Song-Yang Wu, Yi-Zhou Jiang, Li Chen
Supplementary Table from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f5866ab4f3e90784a490b8e46ab2dcc
https://doi.org/10.1158/1078-0432.22487397.v1
https://doi.org/10.1158/1078-0432.22487397.v1
Autor:
Zhi-Ming Shao, Zhong-Hua Wang, Wen-Tao Yang, Jian-Jun Zou, Xiao-Yu Zhu, Yanhui Xu, Xizi Chen, Xiaomao Guo, Wen-Jun Chai, Xiang-Jie Sun, Ying Xu, Xiao-Yan Ma, Shen Zhao, Xin Hu, A-Yong Cao, Xiao-Yan Huang, Can-Ming Chen, Zhen Hu, Yi-Feng Hou, Jun-Jie Li, Lei Fan, Ke-Da Yu, Guang-Yu Liu, Gen-Hong Di, Jiong Wu, Song-Yang Wu, Yi-Zhou Jiang, Li Chen
Supplementary Figure from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2309b0f1682e17911f052505f61db101
https://doi.org/10.1158/1078-0432.22487400.v1
https://doi.org/10.1158/1078-0432.22487400.v1
Autor:
Zhi-Ming Shao, Zhong-Hua Wang, Wen-Tao Yang, Jian-Jun Zou, Xiao-Yu Zhu, Yanhui Xu, Xizi Chen, Xiaomao Guo, Wen-Jun Chai, Xiang-Jie Sun, Ying Xu, Xiao-Yan Ma, Shen Zhao, Xin Hu, A-Yong Cao, Xiao-Yan Huang, Can-Ming Chen, Zhen Hu, Yi-Feng Hou, Jun-Jie Li, Lei Fan, Ke-Da Yu, Guang-Yu Liu, Gen-Hong Di, Jiong Wu, Song-Yang Wu, Yi-Zhou Jiang, Li Chen
Purpose:Camrelizumab, an mAb against programmed cell death protein 1 (PD-1), plus nab-paclitaxel exhibited promising antitumor activity in refractory metastatic immunomodulatory triple-negative breast cancer (TNBC). Famitinib is a tyrosine kinase inh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0933947e0d4bbbf77ca8537a0f12d16e
https://doi.org/10.1158/1078-0432.c.6532512.v1
https://doi.org/10.1158/1078-0432.c.6532512.v1
Autor:
Fuping Jiang, Song Lin, Nihong Chen, Xiaohan Zheng, Jian-Jun Zou, Juan Zhang, Xiaoli Cui, Junshan Zhou, Jinsong Chen, Fusang Wang
Publikováno v:
International Journal of Cardiology. 347:21-27
Background Selecting best candidates for prolonged poststroke cardiac monitoring in acute ischemic stroke (AIS) patients is still challenging. We aimed to develop a machine learning (ML) model to select AIS patients at high risk of poststroke atrial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cfd78feaa78e0bfdfa08ae16f6f0ee7
https://doi.org/10.1016/j.ijcard.2021.11.005
https://doi.org/10.1016/j.ijcard.2021.11.005
Autor:
Jian-jun Zou, Yifan Zhang, Dafang Zhong, Xiao-fei Chen, Xin liang, Y. L. Zhu, Yan-mei Liu, Qian Chen, Hai-yan Liu, Jingying Jia, Zhendong Chen, Chen Yu, Yan Zhan
Publikováno v:
Clinical Therapeutics. 43:e264-e273
Purpose Henagliflozin is a highly selective and effective sodium glucose co-transporter (SGLT)-2 inhibitor developed for the treatment of patients with type 2 diabetes mellitus (T2DM). This study aimed to investigate the effects of meal intake on the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e64897d6114b818afbcc628b566b7ae6
https://doi.org/10.1016/j.clinthera.2021.07.008
https://doi.org/10.1016/j.clinthera.2021.07.008